Spironolactone therapy in heart failure patients with chronic kidney disease

Clinical Cardiology

Volumn 32, Issue 10, 2009, Pages 597-

  Lopes, Ricardo ^a   Lourenco, Patricia ^a   Mascarenhas, Joana ^a   Azevedo, Ana ^a   Bettencourt, Paulo ^a  

^a HOSPITAL DE SÃO JOÃO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; NONSTEROID ANTIINFLAMMATORY AGENT; POTASSIUM; SPIRONOLACTONE;

CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE EXACERBATION; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPOALDOSTERONISM; LETTER; POTASSIUM BLOOD LEVEL; RISK FACTOR;

ALDOSTERONE ANTAGONISTS; BIOLOGICAL MARKERS; CHRONIC DISEASE; CREATININE; HEART FAILURE; HUMANS; HYPERKALEMIA; KIDNEY DISEASES; POTASSIUM; SPIRONOLACTONE;

EID: 70849127053     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.20670     Document Type: Letter

References (3)

1. Kandula P, Sham R. Safety of spironolactone use in ambulatory heart failure patients. Clin Cardiol. 2009;32(6):347-348.
2. Lopes RJ, Lourenço AP, Mascarenhas J, Azevedo A, Bettencourt P. Safety of spironolactone use in ambulatory heart failure patients. Clin Cardiol.. 2008;31(11):509-513.
3. Wencker D. Acute cardio-renal syndrome: progression from congestive heart failure to congestive kidney failure. Curr Heart Fail Rep. 2007;4(3):134-138. (Pubitemid 47493058)